Supplemental Oxygen in Pulmonary Fibrosis
| Status: | Recruiting |
|---|---|
| Conditions: | Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | October 2013 |
| End Date: | September 2016 |
| Contact: | Amanda Belkin, MPH |
| Email: | support@PFresearch.org |
| Phone: | 855-609-0010 |
Observing the Effects of Supplemental Oxygen on Patients With Pulmonary Fibrosis
To enhance understanding of supplemental oxygen—its utility in and adoption by patients with
pulmonary fibrosis—by examining how patients perceive it and by determining how perceptions
and patient-centered outcome measures change from before to after supplemental oxygen is
prescribed.
pulmonary fibrosis—by examining how patients perceive it and by determining how perceptions
and patient-centered outcome measures change from before to after supplemental oxygen is
prescribed.
The investigators aim to recruit patients with PF to participate in interviews and/or a
one-year study of supplemental oxygen (O2). In the one-year study, the investigators will
collect data before and for one year after PF patients are prescribed daily-use supplemental
oxygen and compare outcomes, including shortness of breath, quality of life, fatigue, cough,
and day-to-day functioning before and after O2.
In addition to this, the investigators will interview O2 prescribers and primary
supporters/caregivers of PF patients prescribed daily-use O2 to understand the perceptions
of others affected by supplemental O2.
one-year study of supplemental oxygen (O2). In the one-year study, the investigators will
collect data before and for one year after PF patients are prescribed daily-use supplemental
oxygen and compare outcomes, including shortness of breath, quality of life, fatigue, cough,
and day-to-day functioning before and after O2.
In addition to this, the investigators will interview O2 prescribers and primary
supporters/caregivers of PF patients prescribed daily-use O2 to understand the perceptions
of others affected by supplemental O2.
Inclusion Criteria:
Patient-Participants
(Using daily 02 therapy at time of enrollment)
- Diagnosis of PF
- Able to read and speak English
- Has been on daily-use supplemental oxygen for more than one year
(Not using daily 02 therapy at time of enrollment)
- Diagnosis of PF
- Able to read, speak and write in English
- Has not been prescribed daily-use supplemental oxygen
- Forced vital capacity <75% and diffusing capacity <65% of predicted values
- Subject's physician allows the subject to abstain from daily-use supplemental oxygen
for 7-10 days after prescription to allow data for collection
Primary Supporters
- Self-report status of providing care or support to a person living with pulmonary
fibrosis who has used supplemental oxygen for more than one year
- Able to speak English
O2 Prescribers
- Self-report status of being a prescriber of daily-use supplemental oxygen to PF
patients
- Able to speak English
We found this trial at
1
site
Click here to add this to my saved trials
